Davis Selected Advisers grew its holdings in Davis Select U.S. Equity ETF (NASDAQ:DUSA) by 33.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,340,700 shares of the healthcare company’s stock after purchasing an additional 334,800 shares during the quarter. Davis Selected Advisers’ holdings in Davis Select U.S. Equity ETF were worth $28,208,000 as of its most recent filing with the SEC.

Separately, Stratos Wealth Partners LTD. acquired a new position in Davis Select U.S. Equity ETF in the second quarter worth $280,000.

Davis Select U.S. Equity ETF (NASDAQ:DUSA) traded up 0.24% during trading on Wednesday, reaching $20.97. The company’s stock had a trading volume of 565 shares. The company’s 50 day moving average price is $21.28 and its 200-day moving average price is $20.79. Davis Select U.S. Equity ETF has a 1-year low of $19.79 and a 1-year high of $21.78.

ILLEGAL ACTIVITY NOTICE: “Davis Select U.S. Equity ETF (DUSA) Holdings Boosted by Davis Selected Advisers” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/06/davis-select-u-s-equity-etf-dusa-holdings-boosted-by-davis-selected-advisers.html.

Davis Select U.S. Equity ETF Company Profile

DUSA Pharmaceuticals, Inc (DUSA) is a vertically integrated dermatology company. The Company is developing and marketing Levulan photodynamic therapy (Levulan PDT). The Company’s marketed products include Levulan Kerastick 20% topical solution with PDT and the BLU-U brand light source. Levulan Kerastick and BLU-U are used for the treatment of non-hyperkeratotic actinic keratoses (AKs), of the face or scalp.

Receive News & Stock Ratings for Davis Select U.S. Equity ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davis Select U.S. Equity ETF and related stocks with our FREE daily email newsletter.